Theodore O’Neill: Thank you very much. I recognize that you don’t want to give out any milestones for the Co-Dx PCR, but if this works pretty much as you expect, this ought to be a product before the end of 2024, can I make that assumption?
Dwight Egan: I’m very comfortable with that assumption, Teo.
Theodore O’Neill: Okay
Dwight Egan: I mean frankly, it’s got to be a lot earlier from our standpoint than 2024 in terms of our expectations. Let’s put it that way. I mean, these clinical trials should not drag on indefinitely. They should be able to be completed in due course. And then we do the analytics that are driven by the data and then we do our submission and we have a device that represents a lot of great new technology. It emphasizes at home and point of care. These are areas that the FDA has stated that they are interested in, let’s say, from a priority standpoint. So we expect — we don’t know this, but we expect that we will get appropriate attention from the regulators in terms of getting this on to the market. I think people who look at our product and look at its capabilities in terms of real time PCR and the ability to set up a terrific surveillance sort of system in terms of being in the cloud for the diagnostics and the data availability to healthcare professionals and doctors and state health departments and such.
And when they look at the accuracy of the tests and when they look at the fact that we can multiplex in sort of a class by ourselves, because we’re not only using PCR, we’re using Co-Primers, which enhances the ability to multiplex measurably. And so, I mean, if I can be so bold as to just say, we believe our product is at the top of the heap in terms of specifications and we think it is the best also in terms of price. And ultimately, we think this comes down to price specifications from a competitive standpoint. And we think we — I think we win the race on both of those metrics.
Theodore O’Neill: Okay. And Brian, a question for you. I’m just trying to get my head around the goodwill impairment charge and the gain on re-measurement of acquisition contingencies. If those are both related to Idaho Molecular and Advanced Conceptions, could I simplistically net those two together?
Brian Brown: Simplistically maybe you could for now, but here is the differences. When you impaired goodwill, it never gets written back up. It’s gone forever. On the revalue, the re-measurement of those contingencies as the stock price goes back up, we will have to increase the value of those, which will automatically — it will take a hit on the P&L where we’ve taken the gain for the year. So that’s the difference between .
Theodore O’Neill: Yes. Okay. All right. Thank you very much.
Operator: And this concludes our question-and-answer session. I’d like to turn the conference back over to Dwight Egan for any closing remarks.
Dwight Egan: Well, it’s no secret that COVID created a fulcrum that allowed Co-Diagnostics to leverage our state-of-the-art patented Co-Primers PCR technology to help more people than ever before and increase our profile both domestically and internationally. But more important than what we have done is what we believe we will yet accomplish. In short, our greatest impact is yet to come. A device that is the first to market is less significant than the device that is the first to do it right. And that has been our goal since the beginning. We are pleased with the progress the company has made in developing a long term strategy around our exceptional new Co-Dx PCR home platform, not just for COVID, but for a whole range of diseases such as flu, RSV, STIs, tuberculosis and others.
